Literature DB >> 25783204

The cost-benefit of federal investment in preventing Clostridium difficile infections through the use of a multifaceted infection control and antimicrobial stewardship program.

Rachel B Slayton1, R Douglas Scott1, James Baggs1, Fernanda C Lessa1, L Clifford McDonald1, John A Jernigan1.   

Abstract

OBJECTIVE: To determine the potential epidemiologic and economic value of the implementation of a multifaceted Clostridium difficile infection (CDI) control program at US acute care hospitals
DESIGN: Markov model with a 5-year time horizon PARTICIPANTS: Patients whose data were used in our simulations were limited to hospitalized Medicare beneficiaries ≥65 years old.
BACKGROUND: CDI is an important public health problem with substantial associated morbidity, mortality, and cost. Multifaceted national prevention efforts in the United Kingdom, including antimicrobial stewardship, patient isolation, hand hygiene, environmental cleaning and disinfection, and audit, resulted in a 59% reduction in CDI cases reported from 2008 to 2012.
METHODS: Our analysis was conducted from the federal perspective. The intervention we modeled included the following components: antimicrobial stewardship utilizing the Antimicrobial Use and Resistance module of the National Healthcare Safety Network (NHSN), use of contact precautions, and enhanced environmental cleaning. We parameterized our model using data from CDC surveillance systems, the AHRQ Healthcare Cost and Utilization Project, and literature reviews. To address uncertainty in our parameter estimates, we conducted sensitivity analyses for intervention effectiveness and cost, expenditures by other federal partners, and discount rate. Each simulation represented a cohort of 1,000 hospitalized patients over 1,000 trials. RESULTS In our base case scenario with 50% intervention effectiveness, we estimated that 509,000 CDI cases and 82,000 CDI-attributable deaths would be prevented over a 5-year time horizon. Nationally, the cost savings across all hospitalizations would be $2.5 billion (95% credible interval: $1.2 billion to $4.0 billion).
CONCLUSIONS: The potential benefits of a multifaceted national CDI prevention program are sizeable from the federal perspective.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25783204      PMCID: PMC6550306          DOI: 10.1017/ice.2015.43

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  9 in total

1.  Intestinal bile acids directly modulate the structure and function of C. difficile TcdB toxin.

Authors:  John Tam; Simoun Icho; Evelyn Utama; Kathleen E Orrell; Rodolfo F Gómez-Biagi; Casey M Theriot; Heather K Kroh; Stacey A Rutherford; D Borden Lacy; Roman A Melnyk
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-09       Impact factor: 11.205

2.  Evaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Incidence Rate of Healthcare-Associated Clostridium difficile Infection: A Non-Randomized, Stepped Wedge, Single-Site, Observational Study.

Authors:  Giulio DiDiodato; Leslie McArthur
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

Review 3.  Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations.

Authors:  Evelyn Balsells; Teodora Filipescu; Moe H Kyaw; Camilla Wiuff; Harry Campbell; Harish Nair
Journal:  J Glob Health       Date:  2016-12       Impact factor: 4.413

4.  Development and validation of a time and motion guide to assess the costs of prevention and control interventions for nosocomial infections: A Delphi method among experts.

Authors:  Eric Tchouaket Nguemeleu; Sandra Boivin; Stephanie Robins; Drissa Sia; Kelley Kilpatrick; Sylvain Brousseau; Bruno Dubreuil; Catherine Larouche; Natasha Parisien
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

Review 5.  Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs: A Narrative Review.

Authors:  Fazlollah Keshavarzi
Journal:  Iran J Med Sci       Date:  2022-09

6.  Vital Signs: Estimated Effects of a Coordinated Approach for Action to Reduce Antibiotic-Resistant Infections in Health Care Facilities - United States.

Authors:  Rachel B Slayton; Damon Toth; Bruce Y Lee; Windy Tanner; Sarah M Bartsch; Karim Khader; Kim Wong; Kevin Brown; James A McKinnell; William Ray; Loren G Miller; Michael Rubin; Diane S Kim; Fred Adler; Chenghua Cao; Lacey Avery; Nathan T B Stone; Alexander Kallen; Matthew Samore; Susan S Huang; Scott Fridkin; John A Jernigan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-08-07       Impact factor: 17.586

7.  Economic burden of Clostridium difficile in five hospitals of the Florence health care system in Italy.

Authors:  Anna Poli; Sergio Di Matteo; Giacomo M Bruno; Enrica Fornai; Maria Chiara Valentino; Giorgio L Colombo
Journal:  Risk Manag Healthc Policy       Date:  2015-11-18

Review 8.  Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015.

Authors:  Joana Carmo; Susana Marques; Iolanda Chapim; Maria Ana Túlio; José Pedro Rodrigues; Miguel Bispo; Cristina Chagas
Journal:  GE Port J Gastroenterol       Date:  2015-08-31

9.  Clinical impact of a Clostridioides (Clostridium) difficile bedside infectious disease stewardship intervention.

Authors:  María Olmedo; Maricela Valerio; Elena Reigadas; Mercedes Marín; Luis Alcalá; Patricia Muñoz; Emilio Bouza
Journal:  JAC Antimicrob Resist       Date:  2020-08-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.